Curis To Announce Positive Updates On Emavusertib Studies For Lymphoma And Lymphociytic Leukemia July 22
Curis, Inc.
Curis, Inc. CRIS | 0.00 |
Curis To Announce Positive Updates On Emavusertib Studies For Lymphoma And Lymphociytic Leukemia July 22
